Methamphetamine Use Disorder Clinical Trial
Official title:
The Dynamic Network Mechanism for the Risky Decision-making Deficits Among Methamphetamine Dependence Individuals and Its Trans-cranial Current Stimulation
The risky decision-making deficits is the core feature of the methamphetamine (MA) dependence. Our previous research found that MA dependents have network abnormalities such as decision-making and rewarding. The feedback-related negativity amplitude in the prefrontal central area of MA users becomes smaller and blunted after a loss. Moreover, the neural modulation over the prefrontal cortex showed potent to decrease the craving, and the functional connectivity between frontal cortex and subparietal lobules increases. It suggests that there is a correlation between the decision-making network and the reward network of MA addicts, but there is no real-time observation of the dynamic changes of these brain network activities, so it is difficult to correct the interaction mechanism. In order to clarify the dynamic brain network mechanism of the risky decision-making deficits among MA dependents, firstly, based on magneto-encephalography source information reconstruction methods, firstly, based on magneto-encephalography source information reconstruction methods, the investigators will observe the sequence and interaction among decision-making network, rewarding network, and emotion network. Besides, the investigators clarify that the trans-cranial current stimulation over prefrontal cortex could improve the speed and intensity of the key network interactions among MA dependents, which could improve risky decision-making and craving. The successful implementation of the study is expected to provide important clues for elucidating the pathological mechanism of risky decision-making deficits in MA dependents and providing a theoretical basis for the treatment of addiction.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04178993 -
Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
|
Phase 1 | |
| Completed |
NCT01982643 -
Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder
|
Phase 1/Phase 2 | |
| Completed |
NCT03078075 -
Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
|
Phase 3 | |
| Terminated |
NCT05711862 -
The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder
|
Phase 2 | |
| Recruiting |
NCT05322954 -
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
|
Phase 1 | |
| Recruiting |
NCT05760807 -
Intranasal Oxytocin for Methamphetamine Withdrawal in Women
|
N/A | |
| Recruiting |
NCT04614584 -
Mirtazapine and Methamphetamine Drug-drug Interaction Study
|
Phase 1 | |
| Not yet recruiting |
NCT06320366 -
Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder
|
N/A | |
| Recruiting |
NCT05558358 -
Deep Brain Stimulation (DBS) for Methamphetamine Use Disorder
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04907357 -
rTMS for Stimulant Use Disorders
|
N/A | |
| Completed |
NCT04713124 -
A Telephone-delievered Intervention to Reduce Methamphetamine Use
|
N/A | |
| Active, not recruiting |
NCT04791969 -
Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM
|
Phase 2 | |
| Completed |
NCT00572234 -
Bupropion in the Treatment of Methamphetamine Dependence
|
N/A | |
| Terminated |
NCT03106571 -
Study of Pomaglumetad and Methamphetamine
|
Phase 1 | |
| Recruiting |
NCT06033365 -
Beginning Early and Assertive Treatment for Methamphetamine Use Disorder
|
N/A |